Amarin Corp Plc (AMRN)

[lowlevelowl88]

There's a thread with Herper on Twitter that provided me much better insight into the MO issue, which is to say I am not sure it was an MO issue at all.

Matt said there's a school of thought among Cardios to approach drugs as a class, and more or less treat them the same. Where so many other FO trials have failed, why did this one succeed, and so robustly? (Obviously we know why.) But MDs who have done a lot less research that most of us re: EPA, still want to treat them as a group of failures, with one large but skepticism-inducing success, which leads to the need to point a finger at something.

Well, it must be the MO, or whatever the argument of the day is.

My heart wants to see Nissen eat it and STRENGTH to fail, but my head thinks we would benefit greatly from a modest benefit to help bring credibility to the "class." Sadly, apparently JELIS and R-IT are not enough to get **everyone** on board, but we'll see how the next 2-3 months go... they might all get left behind on the wrong side of CVD history.